Personalized medicine: Present and future of breast cancer management

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 3, 2014, Pages 223-233

  Sabatier, Renaud ^a   Gonçalves, Anthony ^a   Bertucci, François ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Breast cancer; Molecular profiling; Personalized medicine

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; LAPATINIB; PACLITAXEL; PERTUZUMAB; PROGESTERONE RECEPTOR; TRASTUZUMAB; DNA; TUMOR MARKER;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CLASSIFIER; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; EARLY CANCER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; BIOLOGY; BLOOD; BREAST NEOPLASMS; CLASSIFICATION; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROGNOSIS; TRENDS; TUMOR EMBOLISM;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHATIC METASTASIS; MOLECULAR TARGETED THERAPY; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904652202     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.03.002     Document Type: Review

References (115)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Meadows M. Genomics and personalized medicine. FDA Consum 2005, 39:12-17.
3. Biomarkers surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
4. Guiu S., Michiels S., André F., et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012, 23:2997-3006.
5. Badve S.S., Baehner F.L., Gray R.P., et al. Estrogen- and progesterone-receptor status in ECOG 2197 comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008, 26:2473-2481.
6. Noske A., Loibl S., Darb-Esfahani S., et al. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat 2011, 126:109-117.
7. Jacquemier J., Spyratos F., Esterni B., et al. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer 2013, 13:351.
8. Symmans W.F., Hatzis C., Sotiriou C., et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010, 28:4111-4119.
9. Jänicke F., Prechtl A., Thomssen C., et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001, 93:913-920.
10. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
11. Bertucci F., Houlgatte R., Nguyen C., Viens P., Jordan B.R., Birnbaum D. Gene expression profiling of cancer by use of DNA arrays: how far from the clinic?. Lancet Oncol 2001, 2:674-682.
12. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
13. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
14. Yu K., Lee C.H., Tan P.H., Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004, 10:5508-5517.
15. Bertucci F., Finetti P., Rougemont J., et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004, 64:8558-8565.
16. Weigelt B., Hu Z., He X., et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005, 65:9155-9158.
17. Jacquemier J., Boher J.-M., Roche H., et al. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res 2011, 13:R109.
18. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.-J. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
19. Cheang M.C.U., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
20. Parker J.S., Mullins M., Cheang M.C.U., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
21. Goldhirsch A., Winer E.P., Coates A.S., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206-2223.
22. Dowsett M., Nielsen T.O., A'Hern R., et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664.
23. De Azambuja E., Cardoso F., de Castro G., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513.
24. Penault-Llorca F., André F., Sagan C., et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2809-2815.
25. Stuart-Harris R., Caldas C., Pinder S.E., Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334.
26. Pathmanathan N., Balleine R.L., Jayasinghe U.W., et al. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer. J Clin Pathol 2014, DOI 10 1136/jclinpath-2013-201793.
27. Hugh J., Hanson J., Cheang M.C.U., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27:1168-1176.
28. Viale G., Regan M.M., Mastropasqua M.G., et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008, 100:207-212.
29. Denkert C., Loibl S., Müller B.M., et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013, 24:2786-2793.
30. Irizarry R.A., Warren D., Spencer F., et al. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005, 2:345-350.
31. Shi L., Campbell G., Jones W.D., et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28:827-838.
32. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
33. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65.
34. Van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
35. Van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
36. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192.
37. ®) among breast cancer patients with 4-9 positive lymph nodes. Breast 2013, 22:682-690.
38. Mook S., Schmidt M.K., Weigelt B., et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010, 21:717-722.
39. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
40. Knauer M., Mook S., Rutgers E.J.T., et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010, 120:655-661.
41. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
42. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.
43. Dowsett M., Cuzick J., Wale C., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28:1829-1834.
44. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23:7265-7277.
45. Chang J.C., Makris A., Gutierrez M.C., et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 2008, 108:233-240.
46. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
47. Ma X.-J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
48. Jerevall P.-L., Ma X.-J., Li H., et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011, 104:1762-1769.
49. Ma X.-J., Salunga R., Dahiya S., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008, 14:2601-2608.
50. Mathieu M.C., Mazouni C., Kesty N.C., et al. Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2012, 23:2046-2052.
51. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272.
52. Liedtke C., Hatzis C., Symmans W.F., et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009, 27:3185-3191.
53. Filipits M., Rudas M., Jakesz R., et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011, 17:6012-6020.
54. Dubsky P., Filipits M., Jakesz R., et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2013, 24:640-647.
55. Cuzick J., Dowsett M., Pineda S., et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011, 29:4273-4278.
56. Hassett M.J., Silver S.M., Hughes M.E., et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012, 30:2218-2226.
57. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
58. Sparano J.A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008, 26:721-728.
59. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006, 24:4236-4244.
60. Tabchy A., Valero V., Vidaurre T., et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010, 16:5351-5361.
61. Desmedt C., Di Leo A., de Azambuja E., et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011, 29:1578-1586.
62. Bertucci F., Borie N., Roche H., et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011, 127:363-373.
63. Pierga J.-Y., Asselain B., Alsafadi S. A prospective randomized trial evaluating gene expression arrays to select neoadjuvant chemotherapy regimen for operable breast cancer: First report of the REMAGUS04 trial. Ann Oncol 2012, 23(Suppl. 9):ixe1-ixe30. Abstract 2450.
64. Osborne C.K., McGuire W.L. The use of steroïd hormone receptors in the treatment of human breast cancer: a review. Bull Cancer 1979, 66:203-209.
65. Heuson J.C., Longeval E., Mattheiem W.H., Deboel M.C., Sylvester R.J., Leclercq G. Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancer. Cancer 1977, 39:1971-1977.
66. Byar D.P., Sears M.E., McGuire W.L. Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 1979, 15:299-310.
67. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008, 26:1642-1649.
68. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544-5552.
69. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
70. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
71. Brennan M.J., Donegan W.L., Appleby D.E. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 1979, 137:260-262.
72. Kamby C., Rasmussen B.B., Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989, 60:252-257.
73. Nedergaard L., Haerslev T., Jacobsen G.K. Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies. Acta Pathol Microbiol Immunol Scand 1995, 103:20-24.
74. Lower E.E., Glass E.L., Bradley D.A., Blau R., Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005, 90:65-70.
75. Guarneri V., Giovannelli S., Ficarra G., et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008, 13:838-844.
76. Simmons C., Miller N., Geddie W., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504.
77. Liedtke C., Broglio K., Moulder S., et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958.
78. Lindström L.S., Karlsson E., Wilking U.M., et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30:2601-2608.
79. Gancberg D., Di Leo A., Cardoso F., et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13:1036-1043.
80. Gong Y., Booser D.J., Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769.
81. Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005, 93:552-556.
82. Niikura N., Liu J., Hayashi N., et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012, 30:593-599.
83. Wilking U., Karlsson E., Skoog L., et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011, 125:553-561.
84. Curigliano G., Bagnardi V., Viale G., et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 2011, 22:2227-2233.
85. Dieci M.V., Barbieri E., Piacentini F., et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol 2013, 24:101-108.
86. Botteri E., Disalvatore D., Curigliano G., et al. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast 2012, 21:284-288.
87. Amir E., Miller N., Geddie W., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012, 30:587-592.
88. Amir E., Clemons M., Purdie C.A., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012, 38:708-714.
89. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
90. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
91. Nolé F., Munzone E., Zorzino L., et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008, 19:891-897.
92. Liu M.C., Shields P.G., Warren R.D., et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009, 27:5153-5159.
93. Nakamura S., Yagata H., Ohno S., et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010, 17:199-204.
94. Pierga J.-Y., Hajage D., Bachelot T., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23:618-624.
95. Bidard F.-C., Mathiot C., Degeorges A., et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010, 21:1765-1771.
96. Giuliano M., Giordano A., Jackson S., et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011, 13:R67.
97. Bidard F.-C., Baffert S., Hajage D., et al. Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial. Cancer Res 2012, 72. Abstract nr OT3-4-06.
98. Smerage J.B., Barlow W.E., Hayes D.F., Winer E.P., Leyland-Jones B., Srkalovic G. A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. San Antonio Breast Cancer Symposium 2013, abstract S5-07.
99. Bidard F.-C., Fehm T., Ignatiadis M., et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013, 32:179-188.
100. Leary R.J., Sausen M., Kinde I., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012, 4. 162ra154.
101. Forshew T., Murtaza M., Parkinson C., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012, 4. 136ra68.
102. Dawson S.-J., Tsui D.W.Y., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368:1199-1209.
103. Murtaza M., Dawson S.-J., Tsui D.W.Y., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
104. Rodrigues M.J., Gomez-Roca C. Role of high-throughput sequencing in oncology. Bull Cancer 2013, 100:295-301.
105. Ellis M.J., Ding L., Shen D., et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
106. Shah S.P., Roth A., Goya R., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
107. Stephens P.J., Tarpey P.S., Davies H., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404.
108. Banerji S., Cibulskis K., Rangel-Escareno C., et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
109. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
110. Bild A.H., Parker J.S., Gustafson A.M., et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 2009, 11:R55.
111. Von Hoff D.D., Stephenson J.J., Rosen P., et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010, 28:4877-4883.
112. Tsimberidou A.-M., Iskander N.G., Hong D.S., et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012, 18:6373-6383.
113. Le Tourneau C., Kamal M., Trédan O., et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol 2012, 7:253-265.
114. Andre F. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): a prospective multicentric trial (SAFIR01). J Clin Oncol 2013, 31(Suppl.). abstr 511.
115. Navin N., Krasnitz A., Rodgers L., et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010, 20:68-80.